Anti-CD40 Antibodies for Refractory Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new therapeutic agents and strategies to treat inflammatory diseases and autoimmune diseases, particularly for patients refractory to treatment with anti-CD20 antibodies like rituximab, as some patients develop resistance or do not respond to initial therapy.
Innovation Solution
The use of anti-CD40 antibodies, such as CHIR-12.12, which bind to specific epitopes on the CD40 antigen, compete with CD40L, and mediate potent antibody-dependent cellular cytotoxicity (ADCC), offering an alternative treatment option for patients heterozygous or homozygous for the FcγRIIIa-158F genotype, and are effective in treating inflammatory and autoimmune diseases associated with CD40-expressing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD20 antibodies like rituximab are used to treat inflammatory and autoimmune diseases, then some patients respond to therapy, but many patients develop resistance or do not respond, limiting treatment effectiveness
Solution Approach 1:
The patent changes the therapeutic target parameter from CD20 to CD40, creating a new treatment approach for patients who do not respond to anti-CD20 therapy. This parameter change enables treatment of refractory patients by targeting a different antigen on B cells and other immune cells, thereby improving treatment effectiveness for populations resistant to rituximab
Solution Approach 2:
Instead of continuing to use anti-CD20 antibodies for all patients, the patent inverts the approach by developing anti-CD40 antibodies specifically for patients who failed anti-CD20 treatment. This inversion creates a sequential therapy strategy where the second approach (anti-CD40) is designed to work where the first approach (anti-CD20) failed
2Reliability
If anti-CD40 antibodies are used to treat inflammatory diseases, then therapeutic effects are achieved in refractory patients, but treatment is limited to specific FcγRIIIa genotypes
Solution Approach 1:
The patent applies local quality by tailoring the treatment to specific patient subgroups based on their FcγRIIIa genotype. Rather than attempting to make the antibody universally effective across all genotypes, the invention optimizes for specific genetic populations where the therapy has demonstrated efficacy, accepting that the treatment will have localized rather than universal applicability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Anti-CD40 antibodies like CHIR-12.12 provide a therapeutic option for patients resistant to rituximab by effectively inhibiting CD40 signaling and mediating ADCC, offering a treatment for inflammatory and autoimmune diseases that are refractory to other therapies, with a focus on patients with specific FcγRIIIa genotypes.
Implementation Method 1
agonistic anti-CD40 monoclonal antibodies (mAbs) have been shown to mimic the effects of T helper cells in B-cell activation
Implementation Method 2
mediating potent antibody-dependent cellular cytotoxicity (ADCC)
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan®), are also provided. The methods of the present invention find use in treatment of inflammatory diseases and autoimmune diseases that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to inflammatory diseases and autoimmune diseases that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having an inflammatory or autoimmune disease that is non-responsive or refractory to therapy with other therapeutic agents such as anti-CD20 antibodies.